MapLight Therapeutics (MPLT) EBITDA (2024 - 2026)
MapLight Therapeutics (MPLT) posted EBITDA of -$83.4 million for Q4 2025, down 164.71% sequentially from -$31.5 million in Q3 2025, and down 266.06% YoY from $50.2 million in Q4 2024.
Powered by 
Analysis
MapLight Therapeutics (MPLT) EBITDA (2024 - 2026) Analysis & Trends
MapLight Therapeutics has reported EBITDA for 2 years, with the latest figure at -$83.4 million in Q4 2025.
- Quarterly EBITDA fell 266.06% year-over-year to -$83.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$158.5 million (changed N/A YoY) and the FY2025 annual result came in at -$169.1 million, down 103.85% from the prior year.
- EBITDA retreated to -$83.4 million in Q4 2025 per MPLT's latest filing, from -$31.5 million in the prior quarter.
- Over five years, EBITDA peaked at -$20.9 million in Q3 2024 and troughed at -$83.4 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 10 | MapLight Therapeutics | 636.95 Mn | 636.95 Mn | - | -63.55 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -63.55 Mn |
| Dec 31, 2025 | -83.38 Mn |
| Sep 30, 2025 | -31.50 Mn |
| Jun 30, 2025 | -30.66 Mn |
| Dec 31, 2024 | -22.78 Mn |
| Sep 30, 2024 | -20.89 Mn |